Checkpoint-Inhibitor wirksam bei CCR und Magenkarzinom

被引：0
|
作者：
Thomas Riedel
机构：
来源：
Gastro-News | 2018年 / 5卷 / 1期
关键词：
D O I：
10.1007/s15036-018-0336-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：49 / 49
相关论文
共 50 条
  • [21] Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
    Omar Hasan Ali
    Fiamma Berner
    Christoph Jakob Ackermann
    Sandra Stephanie Ring
    Alexandre Moulin
    Joachim Müller
    Eva Markert
    Oltin Tiberiu Pop
    Stefanie Müller
    Stefan Diem
    Thomas Hundsberger
    Lukas Flatz
    Cancer Immunology, Immunotherapy, 2021, 70 : 563 - 568
  • [22] Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
    Ali, Omar Hasan
    Berner, Fiamma
    Ackermann, Christoph Jakob
    Ring, Sandra Stephanie
    Moulin, Alexandre
    Mueller, Joachim
    Markert, Eva
    Pop, Oltin Tiberiu
    Mueller, Stefanie
    Diem, Stefan
    Hundsberger, Thomas
    Flatz, Lukas
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (02) : 563 - 568
  • [23] Assessing the effects of probiotic supplementation in patients with metastatic melanoma on checkpoint-inhibitor therapy
    Vujevic, Andro
    Strikic, Dominik
    Plese, Sven
    Cegec, Ivana
    Turk, Viktorija Erdeljic
    Ausperger, Ksenija Makar
    Mikulic, Iva
    Aumiler, Matea Radacic
    Likic, Robert
    Mercep, Iveta
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 382 - 382
  • [24] Spontaneous Coronary Artery Dissection (SCAD) Under Immune Checkpoint-Inhibitor Therapy
    Spannbauer, Andreas
    Skoro-Sajer, Nika
    Dona, Carolina
    Bartsch, Rupert
    Lamm, Wolfgang
    Gyongyosi, Mariann
    Lang, Irene M.
    Bergler-Klein, Jutta K.
    CIRCULATION, 2023, 148
  • [25] Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality
    Vader, Daniel T.
    Parikh, Ravi B.
    Li, Haojie
    Imai, Kentaro
    Hubbard, Rebecca A.
    Mamtani, Ronac
    JNCI CANCER SPECTRUM, 2022, 6 (04)
  • [26] Tumorassessment bei Immun-Checkpoint-Inhibitor-TherapieTumoransprechen, Progression und PseudoprogressionTumor assessment in immune checkpoint inhibitor therapyTumor response, progression and pseudoprogression
    S. Foller
    H. Oppel-Heuchel
    M.-O. Grimm
    Der Urologe, 2018, 57 (11): : 1316 - 1325
  • [27] Gastrointestinal Infection Prior to Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk for Checkpoint-Inhibitor Colitis
    Shatila, Malek
    Abdul-Baki, Kian
    Rivera, Andres
    Takigawa, Kei
    Lee, Irene J.
    Sullivan, Andrew
    Gupta, Tanvi
    Lu, Linfeng
    Menon, Raakhi
    Khan, Ayesha
    Salim, Hamza
    Baerman, Elliot Axel.
    Cruz, Carolina Colli
    Natha, Cristina M.
    Vemulapalli, Varun
    Coleman, Garrett T.
    Varatharajalu, Krishnavathana
    Zhou, Yan
    Zhang, Hao Chi
    Shafi, Mehnaz A.
    Wang, Yinghong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S823 - S824
  • [28] Breathless Battle: Unmasking Immune Checkpoint-inhibitor Pneumonitis in Cancer Patients A Case Series
    Peralta De Avila, A.
    Torres-Cardenas, C.
    Torres, B. B.
    Oropeza Martinez, V.
    Villegas Lopez, C.
    Esperon Zapata, C.
    Juarez Leon, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [29] IMMUNE CHECKPOINT-INHIBITOR INDUCED ACUTE PANCREATITIS: A NATIONWIDE POPULATION-BASED STUDY
    Abou Saleh, Mohannad
    Alkhayyat, Motasem
    Habash, Alaa
    Kichler, Adam J.
    Mansoor, Emad
    Simons-Linares, C. Roberto
    Vargo, John J.
    Stevens, Tyler
    Chahal, Prabhleen
    GASTROENTEROLOGY, 2020, 158 (06) : S332 - S332
  • [30] Selektiver Aldosteron-Antagonist auch bei Hochrisikopatienten wirksam und sicherSystolische Herzinsuffizienz
    Michael Koczorek
    MMW - Fortschritte der Medizin, 2012, 154 (10) : 64 - 64
12345